CD4 and lung cancer: demonstrated that JHU083 (a glutamine antagonist) increased the infiltration of CD8+ T cells and CD4+ Th1 cells and decreased immunosuppressive cells, such as MDSC, Treg cells, resulting in strengthened immunoprevention of lung cancer.